Versant Ventures
Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.
Business Model:
Revenue: $6M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Versant Ventures Information
Geographic Data
Address: One Sansome Street
City: San Francisco
State: CA
Zip: 94104
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
3,552,464Website Global Rank
3,632Website Monthly Traffic
Twitter Followers
Description
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
Contact Phone:
+14158018100
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 3/2013 | Achaogen | Series D | 18.9M |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 5/2015 | NeuWave Medical | Series C | 25.3M |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 8/2002 | Concuity | Series C | 16.3M |
| 8/2010 | Respicardia | Series C | 0 |
| 3/2009 | Inogen | Series E | 3M |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 6/2004 | Ablation Frontiers | Series A | 3.6M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 2/2006 | Ablation Frontiers | Series B | 15.1M |
| 5/2016 | Nouscom | Series A | 13.6M |
| 4/2005 | ParAllele Bioscience | Convertible Note | 6M |
| 7/2008 | Hicuity Health | Series B | 5M |
| 1/2022 | Nested Therapeutics | Seed Round | 35M |
| 6/2013 | ForSight Labs | Series B | 9.3M |
| 1/2001 | Cameron Health | Series A | - |
| 1/2006 | Ambrx | Series B | 5M |
| 3/2009 | NovaLign Orthopaedics | Series B | 10M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 7/2006 | GluMetrics | Series B | 9M |
| 11/2017 | Nouscom | Series B | 48.8M |
| 5/2014 | Ceterix Orthopaedics | Series B | 18M |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 7/2019 | Century Therapeutics | Series A | 250M |
| 10/2008 | Lutonix | Series B | 20M |
| 1/2014 | Intuity Medical | Venture Round | 5.5M |
| 3/2012 | Sequent Medical | Series C | 26M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 10/2013 | Inceptus | Series A | 4.7M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 12/2005 | Acclarent | Series B | 25M |
| 11/2016 | Intuity Medical | Venture Round | 0 |
| 5/2004 | NeoVista | Series A | 2M |
| 11/2012 | CardiAQ Valve Technologies | Series B | 37.3M |
| 7/2005 | Nanoplex Technologies | Series B | 2.5M |
| 2/2013 | Nuvaira | Series C | 10M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 10/2013 | Inari Medical | Series A | 4.7M |
| 7/2006 | ROX Medical | Series B | 10.1M |
| 6/2008 | ROX Medical | Series C | 33M |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 12/2008 | Hotspur Technologies | Series A | 1.3M |
| 3/2014 | PIQUR Therapeutics | Series A | 32M |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 6/2018 | Akero Therapeutics | Series A | 65M |
| 3/2005 | Ambrx | Series A | 23.4M |
| 9/2014 | Ivantis | Series B | 25M |
| 9/2015 | Veran Medical Technologies | Venture Round | 0 |
| 1/2001 | Salmedix | Series A | - |
| 11/2006 | Intersection Medical Inc | Series B | 5M |
| 8/2011 | Intuity Medical | Series D | 12M |
| 1/2009 | Synosia Therapeutics | Series B | 0 |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 4/2012 | Five Prime Therapeutics | Private Equity Round | 10M |
| 1/2009 | AlterG | Series B | 8M |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 2/2019 | Nuvaira | Equity | 79M |
| 1/2016 | Benvenue Medical | Equity | 23M |
| 1/2010 | The Foundry | Series A | 3M |
| 10/2011 | Realeve | Series C | 32M |
| 6/2013 | Veracyte | Series C | 28M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 8/2001 | Insulet | Series B | 11M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 11/2002 | Skylight Healthcare Systems | Series B | 7.8M |
| 1/2018 | Pandion Therapeutics | Series A | 58M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 1/2017 | Halio | Series C | 65M |
| 11/2003 | NeoGuide Systems | Series B | 0 |
| 12/2017 | Respicardia | Venture Round | 0 |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 1/2017 | Therachon | Series A | 5M |
| 8/2020 | T-knife | Series A | 78.4M |
| 9/2021 | iECURE | Series A | 50M |
| 7/2013 | Audentes Therapeutics | Series A | 30M |
| 4/2014 | AAVLife | Series A | 12M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 9/2019 | Passage Bio | Series B | 110M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 8/2006 | ImpediMed | Venture Round | 3.4M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 4/2007 | NovaCardia | Series B | 18M |
| 10/2013 | Immune Design | Series C | 49M |
| 7/2006 | Ambrx | Series C | 52M |
| 8/2018 | Therachon | Series B | 60M |
| 6/2015 | Sebacia | Series C | 12M |
| 4/2014 | Sequent Medical | Series D | 20M |
| 4/2011 | Halscion, Inc. | Venture Round | 3.5M |
| 7/2004 | LipoSonix | Series C | 27M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 8/2008 | Glaukos | Series D | 35M |
| 6/2009 | Nexis Vision | Series B | 12M |
| 11/2017 | Oyster Point Pharmaceuticals | Series A | 22M |
| 10/2004 | Concuity | Venture Round | 8.3M |
| 8/2021 | Jnana Therapeutics | Series B | 50M |
| 12/2000 | Skylight Healthcare Systems | Series A | - |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 6/2002 | Spiration | Series D | 22M |
| 10/2020 | RayzeBio | Series A | 45M |
| 11/2006 | Neurotech | Series B | 0 |
| 9/2015 | Therachon | Series A | 35M |
| 1/2020 | VectivBio | Series A | 35M |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 7/2020 | Bright Peak Therapeutics | Series A | 35M |
| 10/2015 | Turnstone Biologics | Series A | 11.3M |
| 9/2009 | Helicos BioSciences | Post-IPO Equity | 10M |
| 7/2015 | PIQUR Therapeutics | Series A | 19M |
| 1/2008 | Inogen | Series E | 12.7M |
| 9/2012 | Rox Medical | Series D | 6M |
| 10/2009 | SpaceOAR | Series B | 6.1M |
| 8/2012 | AlterG | Series C | 10M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 11/2006 | Impedance Cardiology Systems | Series B | 5M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 10/2010 | Synosia Therapeutics | Series C | 0 |
| 1/2007 | Synosia Therapeutics | Venture Round | 32.5M |
| 2/2007 | Trius Therapeutics | Series A | 20M |
| 12/2014 | Audentes Therapeutics | Series B | 42.5M |
| 4/2014 | RedBrick Health | Venture Round | 7.5M |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 11/2021 | ViaLase | Series A | 27.3M |
| 1/2017 | Ebb Therapeutics | Series B | 0 |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 2/2008 | PhaseRx | Series A | 20.2M |
| 2/2007 | Inogen | Series D | 22M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 2/2017 | Vividion Therapeutics | Series A | 50M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 3/2018 | Inari Medical | Series C | 20.9M |
| 5/2014 | Anokion | Series A | 37.5M |
| 3/2008 | Spiration | Series G | 18.5M |
| 2/2007 | Vantage Oncology | Series D | 0 |
| 2/2019 | Oyster Point Pharmaceuticals | Series B | 0 |
| 12/2001 | Pharmion | Venture Round | 65M |
| 11/2022 | iECURE | Series A | 0 |
| 8/2021 | T-knife | Series B | 110M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 9/2010 | Okairos | Series B | 20.5M |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 9/2008 | ForteBio | Series C | 25M |
| 6/2009 | Ocular Therapeutix | Series C | 15M |
| 12/2017 | Jnana Therapeutics | Series A | 50M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 7/2008 | Immune Design | Series A | 18M |
| 10/2002 | Insulet | Series C | 22M |
| 3/2009 | NeoVista | Series D | 18M |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 10/2002 | Pharmion | Venture Round | 40M |
| 2/2018 | Quentis | Series A | 48M |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 11/2006 | NewHope Bariatrics | Private Equity Round | 18.5M |
| 12/2019 | Pipeline Therapeutics | Series B | 0 |
| 4/2006 | MedManage Systems | Series D | 10.8M |
| 4/2021 | Capsida | Series A | 50M |
| 9/2014 | Zyga Technology | Series D | 2M |
| 3/2002 | Phenomix | Series A | 12M |
| 3/2004 | Insulet | Series D | 35.5M |
| 9/2014 | AcuFocus | Venture Round | 0 |
| 11/2018 | Aprea | Series C | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 10/2003 | Biospect | Series B | 27M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 6/2004 | Inogen | Series B | 6M |
| 2/2009 | WaveTec Vision | Series C | 20.1M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 5/2012 | Zyga Technology | Series C | 25M |
| 8/2006 | Vantage Oncology | Series C | 0 |
| 5/2011 | WaveTec Vision | Series D | 15.9M |
| 9/2007 | OpGen | Venture Round | 0 |
| 7/2017 | Sebacia | Series D | 0 |
| 10/2006 | Achaogen | Series B | 26M |
| 4/2010 | Groove Biopharma | Series A | 3.9M |
| 7/2010 | Immune Design | Series B | 32M |
| 1/2008 | Confirma | Series C | 0 |
| 10/2005 | ForteBio | Series B | 17.3M |
| 7/2017 | Venatorx Pharmaceuticals | Series B | 42M |
| 9/2001 | Amphora Discovery | Series A | 35M |
| 2/2006 | Insulet Corporation | Series E | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 1/2010 | Intuity Medical | Series D | 64M |
| 5/2007 | WaveTec Vision | Series B | 13M |
| 1/2004 | Intuity Medical | Series B | 0 |
| 6/2021 | LENZ Therapeutics | Series A | 47M |
| 6/2020 | Lycia Therapeutics | Series A | 50M |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
| 4/2006 | Spiration | Series F | 13.4M |
| 1/2004 | Novacea | Series C | 35M |
| 9/2020 | Graphite Bio | Series A | 45M |
| 11/2002 | Novacea | Series B | 36M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 10/2008 | Respicardia | Series B | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 5/2005 | Vantage Oncology | Series C | 0 |
| 5/2020 | Monte Rosa Therapeutics | Series A | 32.5M |
| 4/2007 | Acclarent | Series C | 35M |
| 6/2021 | Stablix | Series A | 63M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 6/2004 | Vantage Oncology | Series B | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2004 | Spiration | Series E | 0 |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 9/2008 | Microfabrica | Series B | 22.5M |
| 1/2011 | Ocular Therapeutix | Series C | 6M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 11/2011 | AcuFocus | Private Equity Round | 0 |
| 6/2008 | Cameron Health | Series E | 0 |
| 4/2015 | Twelve | Series C | 35M |
| 4/2008 | Bird Rock Bio | Series A | 8M |
| 4/2013 | RedBrick Health | Private Equity Round | 14M |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 6/2013 | Ocular Therapeutix | Series D | 23.8M |
| 12/2015 | Kyras Therapeutics | Series A | - |
| 2/2011 | Glaukos | Series E | 0 |
| 9/2006 | NeoVista | Series B | 26M |
| 10/2021 | Tentarix Biotherapeutics | Series A | 50M |
| 8/2012 | ForSight VISION5 | Venture Round | 8M |
| 4/2011 | Benvenue Medical | Series C | 35.5M |
| 3/2009 | LensX Lasers | Series B | 22.4M |
| 4/2014 | ForSight VISION5 | Equity | 15M |
| 2/2017 | Tarveda Therapeutics | Series D | 30M |
| 4/2014 | ForSight Labs | Series C | 15M |
| 4/2015 | CRISPR Therapeutics | Series A | 35M |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 11/2001 | ParAllele Bioscience | Series A | - |
| 3/2018 | Tempest Therapeutics | Series B | 70M |
| 11/2016 | Turnstone Biologics | Series B | 0 |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 8/2011 | RedBrick Health | Series D | 5M |
| 5/2018 | Lava Therapeutics | Series A | 18.7M |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 6/2010 | Veracyte | Series B | 28M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 4/2009 | RedBrick Health | Series C | 15M |
| 5/2009 | Realeve | Series B | 20M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 6/2017 | Monteris Medical | Series C | 26.6M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 1/2007 | AcuFocus | Series D | 0 |
| 12/2008 | CELLutions Biosystems | Series B | 8.8M |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 8/2020 | Matterhorn Biosciences | Venture Round | 30M |
| 12/2015 | Inception IBD | Series A | 14.1M |
| 3/2016 | Aprea | Series B | 50.6M |
| 12/2007 | RedBrick Health | Series B | 15M |
| 11/2002 | Vantage Oncology | Series A | 9M |
| 12/2013 | Inception Sciences | Series A | 10M |
| 5/2001 | CardioNow | Series C | 6M |
| 9/2006 | NovaCardia | Series B | 48M |
| 9/2002 | Glaukos | Series A | 10M |
| 12/2016 | BlueRock Therapeutics | Series A | 225M |
| 5/2008 | Novasys Medical, Inc. | Series D | 49.5M |
| 9/2005 | Kythera Biopharmaceuticals | Seed Round | 1M |
| 4/2008 | Anaphore | Venture Round | 8M |
| 1/2009 | Anaphore | Series A | 25M |
| 4/2005 | NovaCardia | Series A | - |
| 6/2012 | Halscion, Inc. | Debt Financing | 4.3M |
| 10/2005 | Cameron Health | Series C | 15M |
| 12/2000 | Confirma | Series B | 12M |
| 11/2009 | Standard BioTools | Venture Round | 0 |
| 5/2008 | Novasys Health | Venture Round | 49.5M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 1/2008 | Benvenue Medical | Series B | 15M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 11/2003 | Cameron Health | Series B | 29M |
| 9/2010 | Nuvaira | Series A | 3M |
| 4/2014 | Nuvaira | Series D | 42M |
| 6/2004 | Aria Biosystems | Series A | 5.5M |
| 4/2009 | Ambrx | Series D | 10M |
| 3/2008 | Ocular Therapeutix | Series B | 6M |
| 12/2018 | Black Diamond Therapeutics | Series A | 20M |
| 10/2009 | Halscion, Inc. | Venture Round | 6M |
| 10/2012 | Cotera | Venture Round | 5M |
| 12/2016 | Veran Medical Technologies | Venture Round | 31M |
| 9/2003 | ParAllele Bioscience | Series B | 22.5M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 6/2009 | Anaphore | Series A | 13M |
| 9/2019 | Anokion | Series B | 40M |
| 3/2012 | OpGen | Series C | 0 |
| 8/2007 | MedManage Systems | Series E | 5M |
| 1/2004 | Standard BioTools | Series D | 21M |
| 1/2007 | Standard BioTools | Series E | 0 |
| 1/2011 | SpaceOAR | Debt Financing | 3M |
| 4/2014 | CRISPR Therapeutics | Series A | 25M |
| 12/2011 | Groove Biopharma | Series B | 6M |
| 3/2013 | Novira Therapeutics | Series A | 0 |
| 11/2001 | Standard BioTools | Series C | 34M |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 12/2006 | NeoVista | Series C | 41M |
| 5/2010 | Sequent Medical | Series B | 15.6M |
| 10/2020 | VectivBio | Equity | 110M |
| 2/2011 | Ocular Therapeutix | Series D | 14M |
| 7/2006 | Cameron Health | Series D | 31M |
| 10/2012 | Cerephex | Series A | 5.9M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 7/2008 | OraMetrix | Series C | 0 |
| 10/2007 | Vital Therapies | Series C | 28.1M |
| 4/2004 | MedManage Systems | Series C | 6M |
| 11/2008 | CodeRyte | Series D | 0 |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 11/2011 | Hicuity Health | Series D | 0 |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 1/2009 | Bird Rock Bio | Series A | 25M |
| 6/2007 | CELLutions Biosystems | Series B | 7M |
| 6/2002 | Intuity Medical | Series A | 3M |
| 1/2017 | Jecure Therapeutics | Series A | 20M |
| 1/2019 | Halio | Series D | 100M |
| 8/2012 | Intuity Medical | Venture Round | 12M |
| 8/2006 | Intuity Medical | Series C | 20M |
| 4/2004 | ROX Medical | Series A | 3.6M |
| 6/2015 | Inari Medical | Series B | 12.4M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 9/2016 | Rox Medical | Series E | 40M |
| 3/2009 | Rennovia | Series A | 16.3M |
| 6/2012 | Benvenue Medical | Series D | 25M |
| 6/2014 | Benvenue Medical | Series E | 40M |
| 6/2002 | Salmedix | Series B | 27.5M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 12/2003 | Confirma | Venture Round | 3M |
| 8/2019 | Chinook Therapeutics | Series A | 65M |
| 2/2005 | Five Prime Therapeutics | Series C | 45M |
| 9/2005 | Standard BioTools | Series D | 0 |
| 5/2020 | Ventus Therapeutics | Series A | 60M |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 9/2010 | OpGen | Series B | 0 |
| 6/2012 | Twelve | Series B | 15M |
| 1/2008 | Nexis Vision | Series A | 6M |
| 1/2006 | ForSight Labs | Venture Round | 2.4M |
| 4/2007 | ForSight Labs | Series A | 5M |
| 4/2008 | SpaceOAR | Series A | 0 |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 12/2012 | Minerva Surgical | Venture Round | 20M |
| 9/2012 | Nuvaira | Series B | 10.6M |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 1/2018 | Metavention | Series C | 0 |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 11/2022 | iECURE | Series A | 0 |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
